ClinicalTrials.gg
RecruitingNCT06446232Updated Jun 6, 2024

Influenza Vaccine Effectiveness in Among Young Children in Taiwan

An observational study in Influenza Vaccine Allergy, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Influenza, Human with a site in Taiwan — 6 open to participants now, 6 under way, 2 of them phase 3. Influenza, Human · Taiwan.

Started
2023
with 2 others
Observational
5 of 52
1 open now
Registered
43rd of 52
by date
Lead sponsor
5 of 52
National Taiwan University Hospital

Among the 52 studies in Influenza, Human with a site in Taiwan, this one is one of 3 that started in 2023, is one of 5 observational ones, and was the 43rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

6 of the 52 studies in Influenza, Human with a site in Taiwan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Influenza, Human with a site in Taiwan, or all of them as a file.
02

Study summary

This project uses questionnaires to statistically analyze whether influenza vaccination is protective for young children.

Read the detailed description

This plan is expected to admit 350 children who are admitted to the emergency department or hospitalized due to influenza and are aged from 6 months (inclusive) to under 18 years old. Vaccine status, statistical analysis of whether the flu vaccine is protective.

03

Conditions studied

  • Influenza Vaccine Allergy

Browse trials for

Keywords

  • Influenza Vaccine
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Those who have performed a rapid influenza screening test, regardless of whether the result is negative or positive

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of influenza by Flu A+B rapid antigen test
  • Known vaccination status

Exclusion criteria

Exclusion Criteria:

  • Unknown vaccination status
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
1 participant (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Questionnaires

    This project uses questionnaires to statistically analyze whether the flu vaccine is protective for young children. Researchers collect flu rapid test results and invite subjects to write questionnaires. Data collectors administered a standardised questionnaire that included information on demographics, medical history (including flu vaccination status and self-reported prior flu infection).

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.

Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 59 months is above that.

Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jun 6, 2024
StartActual
Sep 1, 2023
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2029
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06446232
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Sep 1, 2023
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Jun 6, 2024

Study contacts

Yi Jen Liau
Contact
u8809032@gmail.com
02-23123456 ext. 271729

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion